Çocukluk Çağı Akut Lösemilerinde Febril Nötropeni: Klinik ve Mikrobiyolojik Değerlendirme

Öz

Amaç: Bu çalışmada, akut lösemi tanılı pediatrik hastalarda kemoterapi ile ilişkili febril nötropeni (FN) ataklarında bakteriyemi sıklığının ve etken mikroorganizmaların belirlenmesi; bakteriyemi ve tedavi sonuçlarıyla ilişkili klinik özelliklerin değerlendirilmesi amaçlandı. Yöntemler: Pediatrik Hematoloji-Onkoloji Kliniği’nde 1 Ocak 2008–31 Aralık 2011 tarihleri arasında akut lösemi tanısıyla takip edilen çocuklarda gelişen FN atakları retrospektif olarak analiz edildi. Klinik ve mikrobiyolojik bulgular, tedavi yönetimi ve mortalite sonuçları değerlendirildi. Bulgular: Tedavi ve takip süresince akut lösemi tanılı 50 çocukta gelişen toplam 260 FN atağı analiz edildi. Atakların %59,6’sında klinik ve/veya mikrobiyolojik olarak kanıtlanmış enfeksiyon saptandı. Bakteriyemi oranı %19,2 idi. İzole edilen etkenlerin %52’si Gram-pozitif bakteriler, %24’ü Gram-negatif bakteriler ve %14’ü fungal patojenlerdi. Başlangıç ampirik tedavisinde başarı oranı %56,5 olup atakların %41,2’sinde tedavi modifikasyonu gerekti. Derin nötropeni, yani mutlak nötrofil sayısının <100/mm³ olması, tedavi başarısızlığı ile anlamlı şekilde ilişkili bulundu (p≤0,001). Mortalite oranı %12 olarak saptandı. Sonuç: Febril nötropeni, akut lösemili çocuklarda önemli bir morbidite ve mortalite nedenidir. Lokal etken dağılımının ve klinik risk özelliklerinin bilinmesi, ampirik antimikrobiyal tedavinin yönlendirilmesi açısından önemlidir. Derin nötropeni tedavi başarısızlığı ile ilişkili bulunmuştur ve klinik risk değerlendirmesinde dikkate alınmalıdır.

Anahtar Kelimeler

• Akut lösemi
• bakteriyemi
• febril nötropeni
• pediatri
• risk sınıflaması

Etik Beyan

Çalışma, yerel Girişimsel Olmayan Klinik Araştırmalar Etik Kurulu tarafından 13 Ocak 2012 tarihinde, 368 sayılı karar ile onaylandı. Çalışma Helsinki Bildirgesi ilkelerine uygun olarak yürütüldü. Retrospektif tasarımı nedeniyle bireysel bilgilendirilmiş onam gerekliliği etik kurul tarafından kaldırıldı.

Febrile Neutropenia in Childhood Acute Leukemia: A Clinical and Microbiological Evaluation

Öz

Objective: This study aimed to determine the frequency of bacteremia and causative microorganisms in chemotherapy-associated febrile neutropenia (FN) episodes in pediatric patients with acute leukemia and to evaluate clinical characteristics associated with bacteremia and treatment outcomes. Methods: Febrile neutropenia episodes occurring in children with acute leukemia who were followed in the Pediatric Hematology-Oncology Clinic between January 1, 2008, and December 31, 2011, were retrospectively analyzed. Clinical and microbiological findings, antimicrobial treatment, and mortality outcomes were evaluated. Results: A total of 260 FN episodes in 50 children with acute leukemia were analyzed. Clinically and/or microbiologically documented infection was detected in 59.6% of episodes, and the bacteremia rate was 19.2%. Of the isolated pathogens, 52% were Gram-positive bacteria, 24% were Gram-negative bacteria, and 14% were fungi. Initial empirical therapy was successful in 56.5% of episodes, whereas treatment modification was required in 41.2%. Profound neutropenia, defined as an absolute neutrophil count <100/mm³, was significantly associated with treatment failure (p≤0.001). Patient-level mortality was 12%. Conclusion: Febrile neutropenia remains an important cause of morbidity and mortality in children with acute leukemia. Knowledge of local pathogen distribution and relevant clinical risk characteristics may help guide empirical antimicrobial therapy. Profound neutropenia was associated with treatment failure and should be considered during clinical risk assessment.

Anahtar Kelimeler

• Acute leukemia
• bacteremia
• febrile neutropenia
• pediatrics
• risk stratification

Kaynakça

1. 1.Lehrnbecher T, Robinson PD, Ammann RA, et al.Guideline for the Management of Fever andNeutropenia in Pediatric Patients With Cancer andHematopoietic Cell Transplantation Recipients:2023 Update. J Clin Oncol. 2023;41(9):1774-85.
2. 2.Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinicalpractice guideline for the use of antimicrobial agentsin neutropenic patients with cancer: 2010 update bythe Infectious Diseases Society of America. ClinInfect Dis. 2011;52(4):e56-e93.
3. 3.Cennamo F, Masetti R, Largo P, et al. Update onFebrile Neutropenia in Pediatric OncologicalPatients Undergoing Chemotherapy. Children(Basel). 2021;8(12):1086.
4. 4.Thursky KA, Singh N, Slavin MA, et al. AustralasianNeutropenic Fever Guidelines Steering Committee.Introduction to the 2024 Consensus Guidelines forthe Management of Neutropenic Fever in Patientswith Cancer: Principles & Practice of NeutropenicFever. Intern Med J. 2025;55(suppl 7):9-19.
5. 5.Haeusler GM, Phillips R, Slavin MA, et al. Re-evaluating and recalibrating predictors of bacterialinfection in children with cancer and febrileneutropenia. EClinicalMedicine. 2020;23:100394.
6. 6.Pui CH, Yang JJ, Hunger SP, et al. Childhood AcuteLymphoblastic Leukemia: Progress ThroughCollaboration. J Clin Oncol. 2015;33(27):2938-48.
7. 7.Ammann RA, Simon A, de Bont ES. Low riskepisodes of fever and neutropenia in pediatriconcology: Is outpatient oral antibiotic therapy thenew gold standard of care? Pediatr Blood Cancer.2005;45(3):244-247.
8. 8.Manji A, Beyene J, Dupuis LL, et al. Outpatient andoral antibiotic management of low-risk febrileneutropenia are effective in children--a systematicreview of prospective trials. Support Care Cancer.2012;20(6):1135-45.

9. 9.Orme LM, Babl FE, Barnes C, et al. Outpatientversus inpatient IV antibiotic management forpediatric oncology patients with low risk febrileneutropenia: a randomised trial. Pediatr BloodCancer. 2014;61(8):1427-33.
10. 10.Sandherr M, Stemler J, Schalk E, et al. 2024update of the AGIHO guideline on diagnosis andempirical treatment of fever of unknown origin(FUO) in adult neutropenic patients with solidtumours and hematological malignancies. LancetReg Health Eur. 2025;51:101214.
11. 11.Erbaş İC, Çakıl Güzin A, Özdem Alataş Ş, et al.Etiology and Factors Affecting Severe Complicationsand Mortality of Febrile Neutropenia in Childrenwith Acute Leukemia. Turk J Haematol.2023;40(3):143-53.
12. 12.Kobayashi R, Sano H, Matsushima S, et al.Analysis of bacteremia at first-line antibiotictreatment for febrile neutropenia in children andadolescents: A retrospective, single-center analysis.J Infect Chemother. 2024;30(7):642-5.
13. 13.Sung L, Aplenc R, Alonzo TA, Gerbing RB, GamisAS; AAML0531/PHIS Group. Predictors and short-term outcomes of hyperleukocytosis in childrenwith acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2012;97(11):1770-3.
14. 14.Matsukawa Y, Matsubayashi J, Sakamoto K, et al.Incidence of Bloodstream Infections in PediatricPatients with Cancer during Febrile Neutropenia: ARetrospective Study. JMA J. 2025;8(2):560-7.
15. 15.Ammann RA, Hirt A, Luthy AR, Aebi C.Identification of children presenting with fever inchemotherapy-induced neutropenia at low risk forsevere bacterial infection. Med Pediatr Oncol.2003;41:436–43.
16. 16.Jungrungrueng T, Anugulruengkitt S,Lauhasurayotin S, et al. The Pattern ofMicroorganisms and Drug Susceptibility in PediatricOncologic Patients with Febrile Neutropenia. JPathog. 2021;2021:6692827.
17. 17.Boeriu E, Borda A, Vulcanescu DD, et al.Diagnosis and Management of Febrile Neutropeniain Pediatric Oncology Patients-A Systematic Review.Diagnostics(Basel). 2022;12(8):1800.
18. 18.Martynov I, Schoenberger J. Impact ofPerioperative Absolute Neutrophil Count on CentralLine-Associated Bloodstream Infection in ChildrenWith Acute Lymphoblastic and Myeloid Leukemia.Front Oncol. 2021;11:770698.
19. 19.Kara SS, Tezer H, Polat M, et al. Risk factors forbacteremia in children with febrile neutropenia.Turk J Med Sci. 2019;49(4):1198-1205.
20. 20.Caniza MA, Odio C, Mukkada S, et al. Infectiouscomplications in children with acute lymphoblasticleukemia treated in low-middle-income countries.Expert Rev Hematol. 2015;8(5):627-45.